Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic

As Boehringer Ingelheim marches on with a €20 billion R&D game plan to get 15 more drugs approved in the next 7 years, it’s shedding another early-stage oncology asset for some cash.